化疗联合内分泌治疗对标准治疗失败晚期转移性乳腺癌的探索性研究

Exploratory study of chemotherapy combined with endocrine therapy for metastatic breast cancer after standard treatment failure

目的 分析化疗与内分泌治疗联合应用于标准治疗失败的晚期转移性乳腺癌的临床价值。方法 30例标准治疗失败的晚期乳腺癌患者，应用依托泊苷[（VP16）75～100 mg，每日1次，连续口服10 d，21 d 为1个周期]联合孕激素类药物（甲羟孕酮 0.5 g，2次／d，或甲地孕酮160 mg，1次／d，连续口服21 d），评价疗效和生活质量。结果 30例患者该次治疗的中位治疗为6线（3～9线），总体临床获益率为16.7 %（5／30），中位无进展生存4.0个月（1.0～13.0个月）。结论 化疗（VP16）联合内分泌（孕激素类药物）治疗标准药物治疗失败的晚期乳腺癌患者是可选择的治疗手段。

Objective To analyze the clinical value of chemotherapy combined with endocine therapy after standard treatment failure for advanced metastatic breast cancer. Methods 30 metastatic breast cancer patients after standard treatment failure were analyzed. Etoposide （75-100 mg/d） wasused on days 1-10, followed by 11 days of rest combined with medroxyprogesterone 0.5 g, twice per day, or megestrol 160 mg/d for 21 days. Clinical effects and life quility were analysed. Results The median treatment line of this therapy was 6 （range 3-9）. The clinical benefit rate is 16.7 % （5/30）, and the median progression free survival （PFS） was 4.0 months （range 1.0-13.0 months）. Conclusion The combination of chemotherapy （etoposide） and endocrine therapy （progesterone） is a choice of treatment after standard drug failure for advanced mastatic breast cancer patients.